English
Arabic
Chinese (Simplified)
Dutch
Esperanto
French
German
Greek
Italian
Japanese
Korean
Portuguese
Russian
Spanish
UrduTen years ago, Tom and Kari Whitehead came to Children’s Hospital of Philadelphia (CHOP) looking for a miracle. Their 6-year-old daughter, Emily, had relapsed in her battle with acute lymphoblastic leukemia (ALL), after many months of unsuccessful chemotherapy and a disease that had progressed so rapidly that she was ineligible for a bone marrow transplant to treat it. Her family came to CHOP in the hopes that Dr. Stephan Grupp, a pioneer in the field of cellular immunotherapy, could provide the miracle they were looking for.
Tag: Acute Lymphoblastic Leukemia
‘Information Theory’ Recruited to Help Scientists Find Cancer Genes
Using a widely known field of mathematics designed mainly to study how digital and other forms of information are measured, stored and shared, scientists at Johns Hopkins Medicine and Johns Hopkins Kimmel Cancer Center say they have uncovered a likely key genetic culprit in the development of acute lymphoblastic leukemia (ALL).
Low-calorie diet and mild exercise improve survival for young people with leukemia
A study led by researchers at UCLA and CHLA has shown that a combination of modest dietary changes and exercise can dramatically improve survival outcomes for those with acute lymphoblastic leukemia, the most common childhood cancer.
Stem Cell Transplants Prevent Relapses of Most Common Childhood Cancer, Study Reveals
Children and young adults who receive CAR T-cell therapy for the most common childhood cancer – acute lymphoblastic leukemia – suffer remarkably fewer relapses and are far more likely to survive when the treatment is paired with a subsequent stem cell transplant, a new study finds.
New NCCN Resource for Understanding Childhood Leukemia
NCCN publishes a new patient and caregiver resource focused on a childhood cancer type. Free NCCN Guidelines for Patients: Pediatric Acute Lymphoblastic Leukemia (ALL) shares the latest expert advice for treating infants, children, and adolescents with the most common pediatric malignancy.
Inherited genetic variant influences response to leukemia treatment for some children
St. Jude researchers showed that an inherited variant of the GATA3 gene is tied to minimal residual disease levels and response to therapy for acute lymphoblastic leukemia.
$500,000 gift supports worldwide effort to harness pediatric cancer data to advance treatment for children
Family looks to the ‘bright side’ by creating a charity to support pediatric cancer research and providing UChicago Medicine Comer Children’s Hospital with $500,000 gift.
Understanding ‘Chemo Brain’ in Children: Researchers Secure $4.6 Million NIH Grant to Identify Those at Risk
Chemotherapy usually cures children diagnosed with acute lymphoblastic leukemia (ALL), but the treatment may hamper brain development and impact key cognitive functions including sensory processing, memory, and attention. Researchers at Albert Einstein College of Medicine, Children’s Hospital at Montefiore (CHAM), and Rutgers Cancer Institute of New Jersey have received a five-year, $4.6 million grant from the National Institutes of Health (NIH) to determine how chemotherapy exerts its damaging effects on the brain. Their long-term objective is to use this information to develop protective interventions that can prevent permanent harm.
Study reveals properties of cells fated to relapse in acute lymphoblastic leukemia
Researchers have found that genetically defined subpopulations of leukemia cells present at diagnosis have distinct characteristics that lead to relapse.
Combination therapy results in 98% response rate for some newly diagnosed leukemia patients
A study combining low-dose chemotherapy with a monoclonal antibody is effective for older patients with Philadelphia chromosome-negative ALL.
Treating the TOTAL patient: clinical trial reduces relapse
A St. Jude Children’s Research Hospital study lowered the rate of relapse for patients with acute lymphoblastic leukemia.
Stephan Grupp, MD, PhD, Elected to the National Academy of Medicine
Stephan Grupp, MD, PhD, Chief of the Cell Therapy and Transplant Section in the Division of Oncology and Director of the Cancer Immunotherapy Program at Children’s Hospital of Philadelphia, has been elected into the National Academy of Medicine (NAM), effective Oct. 1, 2019.